eGenesis Expands Research Collaboration with Leading Academic Medical Center
April 01, 2021 08:00 ET
|
eGenesis
Collaboration will now include in vivo testing of lead kidney xenotransplant program in addition to pancreatic islet xenotransplant program CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) --...
eGenesis Appoints Veteran Financial Executive, Sapna Srivastava, Ph.D., as Chief Financial Officer
March 04, 2021 08:00 ET
|
eGenesis
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the appointment...
eGenesis Announces $125 Million Series C Financing
March 02, 2021 08:00 ET
|
eGenesis
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the successful...
eGenesis Announces Research Collaboration with Leading Academic Medical Center
November 05, 2020 08:30 ET
|
eGenesis
CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs,...
eGenesis Appoints Veteran Biotechnology Development Executive, Michael Curtis, Ph.D., as President of Research & Development
September 01, 2020 08:00 ET
|
eGenesis
CAMBRIDGE, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs,...
eGenesis Appoints Accomplished Biopharmaceutical Executive, Peter Hanson, DVM, Ph.D., as Chief Operating Officer
July 01, 2020 08:00 ET
|
eGenesis
CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs,...
eGenesis Expands Research Collaboration with Massachusetts General Hospital
June 02, 2020 08:00 ET
|
eGenesis
Research collaboration will conduct in vivo testing of lead kidney and islet xenotransplant programs and validate platform in other organs CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) --...
eGenesis Strengthens Production Capabilities with Acquisition of ICBiotec
May 20, 2020 08:00 ET
|
eGenesis
Acquisition enables full integration of R&D and production for ongoing and future xenotransplant programs Contract production partner will become a wholly-owned subsidiary of eGenesis CAMBRIDGE,...
eGenesis Appoints David A. Carmel as Senior Vice President, Public Affairs and Communications
April 06, 2020 08:00 ET
|
eGenesis
NEW YORK & CAMBRIDGE, Mass., April 06, 2020 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of safe and effective...
eGenesis Announces $100 Million Series B Financing
November 07, 2019 06:00 ET
|
eGenesis
Financing led by Fresenius Medical Care Ventures Proceeds will be used to accelerate lead program in kidney xenotransplant into the clinic and progress a range of other xenotransplant programs across...